Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
QURE logo QURE
Upturn stock ratingUpturn stock rating
QURE logo

Uniqure NV (QURE)

Upturn stock ratingUpturn stock rating
$13.25
Delayed price
Profit since last BUY-15.34%
upturn advisory
WEAK BUY
BUY since 43 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/13/2025: QURE (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -65.5%
Avg. Invested days 22
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/13/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 708.05M USD
Price to earnings Ratio -
1Y Target Price 35.65
Price to earnings Ratio -
1Y Target Price 35.65
Volume (30-day avg) 1127621
Beta 0.38
52 Weeks Range 3.73 - 19.18
Updated Date 02/18/2025
52 Weeks Range 3.73 - 19.18
Updated Date 02/18/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.95

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-02-24
When Before Market
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1776.91%

Management Effectiveness

Return on Assets (TTM) -16.62%
Return on Equity (TTM) -147.57%

Valuation

Trailing PE -
Forward PE 27.93
Enterprise Value 390097218
Price to Sales(TTM) 24.77
Enterprise Value 390097218
Price to Sales(TTM) 24.77
Enterprise Value to Revenue 13.65
Enterprise Value to EBITDA 0.99
Shares Outstanding 53437400
Shares Floating 39962551
Shares Outstanding 53437400
Shares Floating 39962551
Percent Insiders 8.69
Percent Institutions 78.83

AI Summary

Uniqure NV: A Comprehensive Overview

Company Profile

Detailed history and background:

Uniqure NV is a Dutch biotechnology company founded in 2004 through the merger of Dutch and American companies. It focuses on developing and commercializing gene therapies for severe medical conditions. The company's lead product is Glybera, the first gene therapy approved in Europe for the treatment of lipoprotein lipase deficiency, a rare genetic disorder.

Core business areas:

Uniqure focuses on three core business areas:

  • Gene therapy development: Uniqure's primary focus is developing adeno-associated virus (AAV)-based gene therapies for various diseases. Their pipeline includes treatments for hemophilia B, Huntington's disease, and Fabry disease.
  • Contract development and manufacturing: Uniqure also offers contract development and manufacturing (CDMO) services for other companies developing gene therapies. This additional source of revenue and expertise contributes to the company's growth.
  • Glybera commercialization: While Uniqure actively focuses on developing newer treatments, they also ensure the continued commercialization of their approved product, Glybera.

Leadership team and corporate structure:

Uniqure is led by Dr. Matt Kapusta, CEO, and a team of experienced executives with expertise in gene therapy development and commercialization. The company has a global presence with research and development facilities in Amsterdam, the Netherlands, and Lexington, Massachusetts, USA.

Top Products and Market Share:

Top products and offerings:

  • Glybera: An AAV-based gene therapy for lipoprotein lipase deficiency.
  • AMT-061: A gene therapy for Hemophilia B in Phase III clinical trials.
  • AMT-130: A gene therapy for Huntington's disease in Phase I/II clinical trials.
  • AMT-080: A gene therapy for Fabry disease in Phase I/II clinical trials.

Market share:

Glybera holds a significant market share in the treatment of lipoprotein lipase deficiency. AMT-061, upon approval, could potentially capture a substantial portion of the Hemophilia B market. However, the market share of other products in the pipeline depends on their success in clinical trials and regulatory approvals.

Product performance and market reception:

Glybera received positive responses for its efficacy in treating lipoprotein lipase deficiency. However, its high cost and limitations in patient selection have resulted in limited market penetration. The remaining products are still in the clinical trial phase, and their market reception is yet to be determined.

Total Addressable Market (TAM):

The total addressable market for Uniqure's products is estimated to be significant. The global market for gene therapies is expected to reach $30.5 billion by 2027, with Hemophilia B, Huntington's disease, and Fabry disease representing substantial sub-segments.

Financial Performance:

Recent financial statements:

Uniqure's revenue primarily comes from Glybera sales and collaboration agreements. However, the company is yet to achieve profitability. In 2022, Uniqure reported a net loss of $89.2 million with a revenue of $12.2 million.

Year-over-year comparison:

Uniqure's revenue has been fluctuating in recent years. In 2022, it decreased by 42% compared to 2021. However, the company expects revenue growth with the potential approval of AMT-061 and progress in other pipeline programs.

Cash flow and balance sheet:

Uniqure has a strong cash position of $286.4 million as of December 31, 2022, providing sufficient resources for ongoing operations and development activities.

Dividends and Shareholder Returns:

Dividend history:

Uniqure has not yet declared any dividends as it is still in the development stage and focuses on reinvesting its earnings into research and development.

Shareholder returns:

Uniqure's stock performance has been volatile in recent years. The share price has dropped significantly in the past year, reflecting the risks associated with its development stage and clinical trial outcomes.

Growth Trajectory:

Historical growth:

Uniqure has experienced variable growth in recent years, primarily driven by fluctuations in Glybera sales and progress in its pipeline programs.

Future growth projections:

Uniqure's future growth depends on the successful development and commercialization of its pipeline products, particularly AMT-061. The company expects to achieve profitability and significant revenue growth upon product approvals and market expansion.

Product launches and growth initiatives:

Uniqure actively pursues strategic initiatives to drive growth, including:

  • Advancing its pipeline products through clinical trials and regulatory approvals.
  • Expanding its CDMO services to generate additional revenue and expertise.
  • Exploring new partnerships and collaborations to enhance its development and commercialization capabilities.

Market Dynamics:

Industry trends:

The gene therapy market is rapidly evolving with significant advancements in technology and expanding applications. Increased investment, regulatory approvals, and growing patient demand are driving the industry's growth.

Demand-supply scenarios:

The demand for innovative gene therapies is increasing, while the supply is still limited due to the complexities of development and regulatory requirements. This creates a favorable environment for companies like Uniqure to gain a competitive edge.

Technological advancements:

Gene therapy technology is continuously evolving, with advancements in vector design, delivery systems, and editing tools. Uniqure actively embraces these advancements to improve the efficacy and safety of its therapies.

Market positioning and adaptability:

Uniqure holds a strong position in the gene therapy market with its established expertise, diverse pipeline, and CDMO capabilities. The company demonstrates adaptability by embracing new technologies and forging strategic partnerships to stay ahead of the competition.

Competitors:

Key competitors:

  • BioMarin Pharmaceutical Inc. (BMRN)
  • Spark Therapeutics (ONCE)
  • Orchard Therapeutics (ORTX)
  • Pfizer Inc. (PFE)
  • Novartis AG (NVS)

Market share comparison:

Uniqure's current market share is relatively small compared to larger competitors. However, the company's innovative pipeline and growth initiatives have the potential to gain a more significant market share in the future.

Competitive advantages and disadvantages:

Uniqure's competitive advantages include its proprietary technologies, experienced team, and diverse pipeline. However, the company faces challenges such as limited market penetration, financial losses, and competition from established players.

Potential Challenges and Opportunities:

Key challenges:

  • Clinical trial risks: The success of Uniqure's growth depends heavily on the outcome of its clinical trials. Setbacks or delays in trials could negatively impact the company's progress and stock performance.
  • Financial sustainability: Uniqure needs to continue securing funding to support its research and development activities until its products become profitable.
  • Intense competition: Uniqure faces stiff competition from established players with larger resources and market share.

Potential opportunities:

  • Product approvals: Regulatory approvals for AMT-061 and other pipeline products could significantly boost Uniqure's revenue and market share.
  • Strategic partnerships: Partnerships with larger pharmaceutical companies can provide Uniqure with additional funding, expertise, and access to broader markets.
  • Technological advancements: Continuous advancements in gene therapy technology can open up new opportunities for Uniqure to develop more effective and accessible treatments.

Recent Acquisitions:

Uniqure has not made any acquisitions in the past three years.

AI-Based Fundamental Rating:

Uniqure receives an AI-based fundamental rating of 6 out of 10. This rating considers the company's financial health, market position, and future prospects. While Uniqure exhibits promising potential with its innovative product pipeline and strategic initiatives, its current financial performance and competition pose challenges that need to be addressed.

Sources and Disclaimers:

This analysis utilizes data from the following sources:

  • Uniqure NV's annual report
  • Uniqure NV's website
  • SEC filings
  • Market research reports

This information is provided for educational purposes only and should not be considered investment advice. Investing in Uniqure NV carries inherent risks, and investors should conduct thorough research and consult with financial professionals before making any investment decisions.

Disclaimer:

This information is not intended to be a substitute for professional financial advice. Always consult with a qualified financial advisor before making any investment decisions.

About Uniqure NV

Exchange NASDAQ
Headquaters -
IPO Launch date 2007-06-20
CEO & Executive Director Mr. Matthew Craig Kapusta CPA
Sector Healthcare
Industry Biotechnology
Full time employees 480
Full time employees 480

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​